ABRIDGED ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
|
|
- Theodora Moore
- 5 years ago
- Views:
Transcription
1 NULOESIDE/TIDE REVERSE TRANSRIPTASE INHIBITORS (N(t)RTIs) Abacavir AB (Ziagen) Emtricitabine FT (Emtriva) Lamivudine 3T (Epivir) Tenofovir disoproxil fumarate TDF (Viread) Zidovudine AZT, ZDV (Retrovir) N(t)RTI o-formulations Zidovudine/ Lamivudine AZT/3T (ombivir) Tablet: 300mg Generic tablet: 300mg Oral solution: 20mg/mL (brand and generic) apsules: 200mg Oral solution: 10mg/mL Tablets: 100mg, 150mg, 300mg Generic tablets: 100mg, 150mg, 300mg Oral solution: 5mg/mL, 10mg/mL Generic oral solution: 10 mg/ml Tablets: 150mg, 200mg, 250mg, 300mg Generic tablet: 300 mg Oral powder: 40mg/g apsule: 100mg Tablet: 300mg Oral syrup: 10mg/mL Generic capsule, tablet, oral syrup Injection solution: 10mg/mL Tablet: 300mg AZT/150mg 3T Generic tablets available 300mg BID 600mg QD 200mg QD (capsule) 240mg (24 ml) QD oral solution 150mg BID or 300mg QD 300mg QD 300mg BID 200mg TID One tablet (300/150) BID No renal adjustment required mg BID > 6 ontraindicated rl apsule Solution mg Q48h 120mg Q24h mg Q72h 80mg Q24h < 15 or HD 200mg Q96h 60mg Q24h mg QD mg x1, 100mg QD mg x1, 50mg QD < 5 or HD 50mg x1, 25mg QD No hepatic adjustment necessary mg Q48h mg Twice weekly HD 300mg Q7 days No hepatic adjustment necessary < 15 or HD 100mg TID or 300mg QD rl < 50mL/min: not recommended hepatotoxicity, mitochondrial toxicity, lactic acidosis N, V, HSR: fever, malaise, GI s/sx, R; do not re-challenge heck HLA-B*5701 to avoid hypersensitivity reaction HA, N, V HA, N, V N, V, flatulence, renal toxicity, bone mineral density Anemia, HA, N, V Minimal Minimal Minimal hepatotoxicity, mitochondrial toxicity, lactic acidosis See AZT & 3T Increases ddi AU: reduce ddi dose to 250mg QD if given with TDF. Minimal; avoid use with other bone marrow (BM) toxic medications. See AZT & 3T Abacavir / Lamivudine AB/3T (Epzicom) Tablet: 600mg AB/300mg 3T Generic tablets available One tablet (600/300) QD rl < 50mL/min: not recommended ontraindicated in mild-moderate hepatic impairment (PT B or ) See AB & 3T See AB & 3T
2 / Emtricitabine TDF/FT (Truvada) Tenofovir AF/ Emtricitabine TAF/FT (Descovy) (TAF= tenofovir alafenamide) Tenofovir DF/Lamivudine TDF/FT (imduo or Temixys) Tablet: 300mg TDF/200mg FT, 150mg TDF/100mg FT, 200mg TDF/133mg FT, 250mg TDF/167mg FT Tablet: 25mg TAF/200mg FT Tablet: 300 mg 3T/300 mg TDF NON-NULOESIDE REVERSE TRANSRIPTASE INHIBITORS (NNRTIs) Adult Dosing Renal/Hepatic Dose Adjustments Adverse Reactions Potential for Interactions One tablet (300/200) QD One tablet (25/200) QD One tablet (300/300) QD tab Q48h < 30 Not recommended o-formulation can be given if rl 30 ml/min. Not recommended if rl < 30 ml/min or on hemodialysis. No dose adjustment in hild-pugh A or B, No dosing data for hild-pugh rl < 50mL/min: not recommended ESRD on HD: not recommended See TDF & FT See TDF & FT N, LDL/total cholesterol Avoid strong inducers See TDF & 3T rash, hepatotoxicity See TDF & 3T Efavirenz EFV (Sustiva) apsules: 50mg, 200mg (brand and generic) Tablet: 600mg (brand and generic) 600mg QD Initially at HS and preferably on empty stomach No hepatic adjustment; use with caution NS effects: dizziness, insomnia, vivid dreams Inducer, inhibitor, and substrate of liver enzymes Etravirine ETR (Intelence) Tablets: 25mg, 100mg, 200mg 200mg BID No renal dose adjustment A or B No data N ETR is a substrate and inducer of liver enzymes (3A4, 29, 219). Do not co-administer with TPV/r, FPV/r, ATV/r, non-rtv-boosted PIs, & other NNRTIs. Nevirapine NVP (Viramune) Tablet: 200mg (brand and generic) Extended release tablet: 100mg, 400mg (brand and generic) Oral suspension: 10mg/mL (brand and generic) 200mg QDx2wks; then 200mg BID rl 20 < 20 No data Dose ontraindicated in hild-pugh lass B or R, hepatotoxicity Both substrate and inducer of liver enzymes Rilpivirine RPV (Edurant) Tablet: 25mg 25mg QD Take with a normal to high calorie meal No hepatic dose adjustment required NS: depressive disorders, HA, insomnia; rash, increased cholesterol, hepatotoxicity Substrate of YP3A4; contraindicated with strong YP3A inducers. Also contraindicated with proton pump inhibitors. Give histamine receptor antagonists 12h before or 4h after RPV.
3 Doravirine DOR (Pifeltro) Tablet: 100 mg NRTI Pair plus NNRTI o-formulations Efavirenz/ Emtricitabine/ Tablet: 600mg EFV/200mg FT/300mg TDF EFV/FT/TDF (Atripla) Efavirenz/Lamivudine/ EFV/3T/TDF (Symfi) Tablet: 600mg EFV/300mg 3T/300mg TDF Also: 400mg EFV/300mg 3T/300mg TDF (Symfi Lo) 100 mg QD Preferably empty stomach Preferably empty stomach in renal impairment; no data for ESRD or in HD hild-pugh A or B Dose No data Not recommended if rl < 50mL/min Not recommended in hild-pugh lass B or Not recommended if rl < 50mL/min Not recommended in hild-pugh lass B or N, D, HA, dizziness Substrate of YP3A4; contraindicated with strong YP 3A4 inducers (e.g. rifampin, certain anticonvulsants) N, HA, D, NS effects See EFV, FT, TDF Possibly fewer NS effects with lower (i.e. 400mg) EFV dose in Symfi Lo See EFV, 3T, TDF Rilpivirine/ Emtricitabine/ RPV/FT/TDF (omplera) Rilpivirine/ Emtricitabine/ Tenofovir AF RPV/FT/TAF (Odefsey) Tablet: 25mg RPV/200mg FT/300mg TDF Tablet: 25mg RPV/200mg FT/25mg TAF Take with a full meal Take with a full meal Not recommended if rl < 50mL/min No adjustment recommended in mildmoderate hepatic impairment; no data in severe impairment Do not give co-formulation if rl < 30mL/min No dose adjustment in hild-pugh A or B, No dosing data for hild-pugh See RPV, FT, TDF See RPV, FT/TAF See RPV, FT, TDF See RPV, TAF/FT (TAF= tenofovir alafenamide) Doravirine/ Lamivudine/ (DOR/3T/TDF) (Delstrigo) Tablet: 100 mg DOR/300 mg 3T/300 mg TDF rl < 50 ml/min not recommended A or B No data See DOR, 3T, TDF See DOR, 3T, TDF INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) Raltegravir RAL (Isentress, Isentress HD) Tablet: 400mg, 600 mg (HD) *hewable tablets: 25mg, 100mg *Powder for oral suspension: 100mg packets (*These formulations are NOT bioequivalent to 400mg tablet) 400mg BID 1200 mg (2 X 600 mg HD tabs) QD No hepatic dose recommendation; no data in severe impairment N, HA, increased creatine kinase Strong inducers of UGT 1A1 (e.g. rifampin) can decrease RAL concentrations.
4 Dolutegravir DTG (Tivicay) Tablet: 10mg, 25mg, 50mg 50mg QD (TN or TE but INSTI-naïve) 50mg BID (INSTIexperienced or with certain UGT1A/YP3A inducers) NRTI pair + INTEGRASE STRAND TRANSFER INHIBITORS (INSTI) o-formulations Elvitegravir (EVG)/ cobicistat/tdf/ft (Stribild) Elvitegravir (EVG)/ cobicistat/taf/ft (Genvoya) (TAF= tenofovir alafenamide) Dolutegravir (DTG)/AB/3T (Triumeq) Tablet: 150mg EVG/150mg cobicistat/ 200mg FT/300mg TDF Tablet: 150mg EVG/150mg cobicistat/ 200mg FT/10mg TAF Tablet: 50mg DTG/600mg AB/300mg 3T Take with food Take with food ; caution for INSTI-experienced pts with severe renal impairment No dose adjustment for mild or moderate hepatic impairment; PK unknown for severe hepatic impairment rl 70 Dose < 70 Initial use not recommended < 50 ontinued use not recommended HD Not recommended A or B Not recommended an be given in patients with rl < 15mL/min who are on hemodialysis (administer after dialysis completed on HD days). Do not give co-formulation if rl 15-30mL/min. Do not give co-formulation if rl < 15mL/min and NOT on dialysis. No dose adjustment in hild-pugh A or B Not recommended in hild-pugh DTG/AB/3T NOT recommended if rl < 50 ml/min because 3T renal dosing is not possible with co-formulation. DTG/AB/3T NOT recommended in hild- Pugh A or higher. AB dose-reduced if hild- Pugh A. HA, insomnia, increased LFTs N, HA, increased creatine kinase, renal toxicity N, D, HA See DTG, AB. 3T Must establish HLA -B*5701 status of pt (to screen for AB hypersensitivity) Strong inducers of UGT1A or YP3A can decrease DTG levels; metformin; divalent/polyvalent cations; see package insert for dose adjustments or contraindicated combinations. Strong 3A4 inducers can decrease EVG obi is a YP3A inhibitor, which EVG exposure; may exposure to other YP3A substrates ontraindicated with rifampin, lovastatin, simvastatin, sildenafil dosed as Revatio for PAH Strong 3A4 inducers can decrease EVG obi is a YP3A inhibitor, which EVG exposure; may exposure to other YP3A substrates ontraindicated with rifampin, lovastatin, simvastatin, sildenafil dosed as Revatio for PAH Strong inducers of UGT1A or YP3A can decrease DTG levels; metformin; divalent/polyvalent cations; see package insert for dose adjustments or contraindicated combinations. Bictegravir (BI)/TAF/FT (Biktarvy) Tablet: 50mg BI/200mg FT/25mg TAF Do not give co-formulation if rl < 30mL/min Not recommended in hild-pugh D, N, HA Strong inducers of UGT1A or YP3A can decrease BI levels; metformin; divalent/polyvalent cations; see package insert for dose adjustments or contraindicated combinations.
5 NNRTI + INSTI o-formulation Dolutegravir (DTG)/Rilpivirine (RPV) (Juluca) PROTEASE INHIBITORS (PIs) Atazanavir ATV (Reyataz) ATV/c (Evotaz) (c=cobicistat) Tablet: 50mg DTG/25 mg RPV apsules: 150mg, 200mg, 300mg (brand and generic) *Pediatric Powder: 50mg packets (*apsules and pediatric powder are NOT interchangeable) Evotaz tablet: 300mg co-formulated with cobicistat 150mg With a meal TN: 400mg QD TN or TE: 300mg QD + [RTV 100mg QD or cobi 150mg QD] or ATV/cobi one tab QD TN with EFV: 400mg + RTV 100mg No renal dose adjustment for mild-moderate renal dysfunction. Monitor for increased adverse effects if severe impairment (rl < 30) or ESRD. See DTG, RPV See DTG and RPV No dose adjustment in mild or moderate hepatic impairment; PK unknown in severe hepatic impairment hepatotoxicity, lipodystrophy, dyslipidemias, insulin resistance/ hyperglycemia No HD HD (TN) HD (TE) ATV 300mg + RTV 100mg Not recommended B 300mg QD (no RTV) Not recommended bilirubin, EKG changes (rare), kidney stones Substrate and inhibitor of liver enzymes. Boost with RTV when given with TDF. Refer to package insert when given with H-2 blockers or PPIs. Darunavir DRV (Prezista) DRV/c (Prezcobix) (c=cobicistat) DRV/c/TAF/FT (Symtuza) Lopinavir/ ritonavir LPV/r (Kaletra) Ritonavir RTV (Norvir) Tablets: 75mg, 150mg, 400mg, 600mg, 800mg Oral suspension: 100mg/mL Prezcobix tablet: 800mg co-formulated with cobicistat 150mg Symtuza tablet: 800 mg/150mg cobicistat/200mg FT/10 mg TAF Tablets: 100mg/25mg, 200mg/50mg LPV/r Oral solution (brand and generic): 80mg LPV-20mg RTV/mL apsule: 100mg (soft gelatin) Tablet: 100mg Oral solution: 80mg/mL TN or TE with no DRV mutations: 800mg + [RTV 100mg QD or cobi 150 mg QD] or DRV/cobi one tab QD TE w/ 1 DRV mutations: 600mg + RTV 100mg BID Two tablets (200/50 per tablet) BID Four tablets QD (not recommended if 3 LPV mutations) Given mg QD-BID to boost PIs ; DRV/cobi + TDF should not be administered if rl < 70 ml/min No hepatic dose recommendation; not recommended in severe hepatic impairment No hepatic dose recommendation; use with caution Follow recommendations for primary PI for hepatic dose adjustment R, N, D, HA Inhibitor of YP3A D, N, GGT D, N, V Substrate & inhibitor of liver enzymes; contains RTV (potent enzyme inhibitor) Refer to package insert for concomitant dosing with EFV, NVP, FPV, NFV. Significant drug interactions Inhibitor of YP3A and 2D6 Inducer p-glycoprotein
6 OTHERS (Fusion Inhibitors, R5 o-receptor Antagonists, Post-attachment Inhibitors) Maraviroc MV (Selzentry) Tablets: 150mg, 300mg Oral solution: 20mg/mL MV+strong YP3A inhibitor (except TPV): 150mg BID MV+YP3A inducer only: 600mg BID MV+NRTIs, TPV, NVP: 300mg BID When co-administered with potent inducers or inhibitors, MV NOT recommended when rl < 30mL/min or in pts on HD. See package insert for specifics. No hepatic dose recommendation R, cough, fever, musculoskeletal symptoms, hepatotoxicity MV is a substrate of liver enzymes. YP3A inhibitors (w/ or w/o inducers), PIs (except TPV/r) and DLV can increase MV YP3A inducers (w/o inhibitors) can decrease MV Ibaluzimab-uiyk (Trogarzo) Injection: 200 mg/1.33ml single-use vials; must be diluted in 0.9% sodium chloride 2000 mg IV infusion loading dose followed by 800 mg IV infusion q2 weeks No formal studies in pts with renal or hepatic insufficiency; renal impairment is not expected to affect drug PK D, N, R, dizziness No drug-drug interactions conducted; none expected based on drug mechanism of action
COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationAntiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationJULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationExploring HIV in 2017: What a pharmacist needs to know
Exploring HIV in 2017: What a pharmacist needs to know Lifecycle of the HIV virus a. HIV spread through mucous membrane contact, damaged tissue contact, or blood contact with: blood, semen, rectal fluids,
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationtreatment passport 1
treatment passport 1 Why keep a treatment history? Keeping a short record of your treatment history can help in many ways. It can help you understand your health and treatment. It can help if your doctor
More informationMedscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationSculpting a Better Regimen: The ART of HIV Medications
Sculpting a Better Regimen: The ART of HIV Medications Kelly Peddy, PharmD, MPA Clinical Pharmacy Specialist - Ambulatory Care Memorial Hospital of South Bend November 30, 2017 For HealthTrust Members
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationMatters of the HAART: An Update on Current Treatment Options for HIV
Matters of the HAART: An Update on Current Treatment Options for HIV Jason Alegro, PharmD, BCPS Assistant Professor of Clinical Sciences, Roosevelt University Infectious Diseases Clinical Pharmacy Specialist,
More informationThe ABCs of ART: Designing Initial Antiretroviral Regimens for Beginners
The ABCs of ART: Designing Initial Antiretroviral Regimens for Beginners Elizabeth Sherman, PharmD, AAHIVP Faculty South Florida, Southeast AETC Clinical Pharmacist, Memorial Healthcare System Assistant
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationJonathan Cohn MD Wayne State University July 24,
Jonathan Cohn MD Wayne State University July 24, 2017 www.matecmichigan.org jcohn@med.wayne.edu Current HIV Test Sequence 4 th Generation Ag/Ab Combo > Differentiation Assay Abbott Architect Alere Determine
More informationPaediatric antiretroviral therapy.
Paediatric antiretroviral therapy. Guidelines exist for the choice of first line agents, but do not cover second line agents, other than recommending regimes of adequate potency. We would follow PENTA
More informationDisclosures. Goals. US DHHS Guidelines: 1 st Line Therapy. Antiretroviral Therapy Initiation:
Disclosures Antiretroviral Therapy Initiation: From Guidelines to Practice: ART 101 Medical Management of AIDS & Hepatitis December 8, 2017 Research grant support from Gilead Sciences for ongoing work
More informationApproach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationPage 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationFundamentals of Antiretroviral Therapy
Fundamentals of Antiretroviral Therapy Southeast AIDS Education & Training Center HIV Clinical Overview 12 May 2016 Todd Hulgan, MD, MPH Department of Medicine, Division of Infectious Diseases Vanderbilt
More informationGoals. Disclosures. US DHHS Guidelines: 1 st Line Therapy. Antiretroviral Therapy Initiation: Medical Management of AIDS & Hepatitis
Goals Antiretroviral Therapy Initiation: From Guidelines to Practice: ART 101 Medical Management of AIDS & Hepatitis December 6, 2018 Vivek Jain, M.D., M.A.S. Associate Professor of Medicine Division of
More informationOctober 26-28: Training Day 1
Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes
More informationAddressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
More informationStarting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation November
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationHIV for the Non-ID Pharmacist
Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationGuidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters
Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationClinical Pharmacology of Integrase Inhibitors
Clinical Pharmacology of Integrase Inhibitors Dr Marta Boffito MD PhD Head of Clinical Trials, St Stephen Centre (SSAT) Consultant Physician, Chelsea and Westminster Foundation Trust Reader, Imperial College
More informationDDIs, INSTIs, TB and Hepatitis
DDIs, INSTIs, TB and Hepatitis David Back University of Liverpool UK David Back University of Liverpool Rio de Janeiro August 2018 Disclosures Honoraria received for advisory boards and lectures from AbbVie,
More informationAppropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
More informationStarting Immediate Treatment for HIV-1
Starting Immediate Treatment for HIV-1 Ronald P. Hattis, MD, MPH Email: ronhattis@foundation.beyondaids.org Associate Prof. of Preventive Medicine, Loma Linda University Secretary, Beyond AIDS Foundation
More informationHIV Treatment Guidelines
HIV Treatment Guidelines Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Are Treatment Guidelines? Issued by variety of global and country-based
More informationHIV/AIDS Prenatal Care for HIV+ Mothers. 1. Algorithm for Prenatal Screening & Care (Antepartum)
1. Algorithm for Prenatal Screening & Care (Antepartum) 2. Algorithm for Prenatal HIV Screening and Care (Mother refuses screening) 3. Algorithm for Intrapartum Care 4. Prenatal Care for HIV+ Mothers a.
More informationKees Brinkman OLVG- Amsterdam The Netherlands
integrase inhibitors in clinical practice in the Netherlands HIV Clinical Forum 2018 Kees Brinkman OLVG- Amsterdam The Netherlands Disclosures relevant activities to dislose companies advisory boards Gilead
More informationHIV Infection & AIDS in Low- and Middle-Income Countries
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationQuick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
More informationFluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids
Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)
More informationHIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine
HIV Update Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine Rates of Diagnoses of HIV Infection among Adults and Adolescents, 2012 United States and 6 Dependent
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationOverview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationHIV A Step-By-Step Approach In Caring For Our HIV-Infected Patients
HIV 1-2-3 A Step-By-Step Approach In Caring For Our HIV-Infected Patients Jeremy Grindeland, PharmD Justin Jones, PharmD, BCPS, BCCCP Objectives Recognize appropriate indications for initiation of Highly
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationThe New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
The New Agents: Management of Experienced Patients and Resistance Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine T.D. 45 year old man with HIV infection diagnosed in 2000 On multiple
More informationSOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER. HIV and Oral Health in the Era of Antiretroviral Therapy
SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER HIV and Oral Health in the Era of Antiretroviral Therapy SOUTH FLORIDA SE AIDS EDUCATION & TRAINING CENTER Mark Schweizer, DDS MPH Director of Development
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationHuman Immunodeficiency Virus (HIV)
Clinical Practice Guidelines Human Immunodeficiency Virus (HIV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Human Immunodeficiency Virus (HIV). GUIDELINE These are only
More informationFriday afternoon Programme
Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008
More informationApproach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Disclosures: grant support from Gilead, Roche, EBSCO Objectives Apply current guidelines to initial evaluation
More informationA Changing Landscape: New and Pipeline HIV Therapies
A Changing Landscape: New and Pipeline HIV Therapies Sarah Turley, PharmD, BCPS PGY2 Internal Medicine Pharmacy Resident Virginia Commonwealth University Health System Financial Disclosure I have no relevant
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationHIV Update Disclosures
HIV Update 2017 Lori A. Gordon, PharmD, BCPS AQ ID, AAHIVP Clinical Assistant Professor Xavier University of Louisiana College of Pharmacy LPA 2017.07.14 Disclosures Lori A. Gordon, PharmD, reports the
More informationThe Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease
The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project ARV Dosing in End Stage Renal Disease 1. Jayasekara, D., Aweeka, F. T., Rodriguez, R., Kalayjian, R. C., Humphreys, M. H.,
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationMEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP
MEDICATION RELATED ISSUES IN THE HIV PATIENT LEONARD SOWAH, MBChB, MPH, FACP Overview Evalua;on and ini;al of a HIV pa;ent with respect to medica;ons Triaging of pa;ent to determine ideal follow up plan
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationToo small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants Mark Mirochnick, MD Boston University School of Medicine, Boston, MA, USA Full Term Full Term 34 wks
More informationHIV Update Danny Toub MD April 14, 2018 HIV/AIDS Review. bayareaaetc.org
HIV Update 2018 Danny Toub MD dannyt@srhealth.org April 14, 2018 HIV/AIDS Review 1 Case #1 19 yo white MSM SSU student 12/1/17: Preliminary+ 12/4/17: Started ART In care, fully suppressed Case #2 19 yo
More informationHIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time
STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More information30 Years of HIV: An Update on Treatment Guidelines and Beyond
8/3/212 Conflict of Interest Declaration 3 Years of HIV: An Update on Treatment Guidelines and Beyond Blake Max, PharmD, AAHIVE Clinical Associate Professor University of Illinois at Chicago College of
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationHIV Diagnosis and Management 2015 Update. Faria Farhat, MD MedStar Washington Hospital Center
HIV Diagnosis and Management 2015 Update Faria Farhat, MD MedStar Washington Hospital Center Objectives Describe the epidemiology and pathogenesis of HIV infection Highlight HIV diagnosis algorithm and
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationAntiretroviral Pregnancy Registry
Preterm Birth, low birth weight and fetal antiretroviral exposure: Estimated gestational age and birth weight data from singleton live births, 1989 through 31 January 2009 K. Beckerman, J. Albano, M. Martinez-Tristani,
More informationAntiretroviral Therapy
Antiretroviral Therapy Shelley A. Gilroy, MD FACP, FIDSA Albany Medical College October 29, 2013 Disclosures Co Investigator for studies at Albany Medical Center sponsored by Gilead and GSK Pharmaceuticals
More informationOverview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
More information